Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 446

1.

Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.

Bargieri DY, Leite JA, Lopes SC, Sbrogio-Almeida ME, Braga CJ, Ferreira LC, Soares IS, Costa FT, Rodrigues MM.

Vaccine. 2010 Apr 1;28(16):2818-26. doi: 10.1016/j.vaccine.2010.02.004. Epub 2010 Feb 17.

PMID:
20170765
2.

New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.

Bargieri DY, Rosa DS, Braga CJ, Carvalho BO, Costa FT, Espíndola NM, Vaz AJ, Soares IS, Ferreira LC, Rodrigues MM.

Vaccine. 2008 Nov 11;26(48):6132-42. doi: 10.1016/j.vaccine.2008.08.070. Epub 2008 Sep 18.

PMID:
18804504
3.

TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium.

Camacho AG, Teixeira LH, Bargieri DY, Boscardin SB, Soares IS, Nussenzweig RS, Nussenzweig V, Rodrigues MM.

Mem Inst Oswaldo Cruz. 2011 Aug;106 Suppl 1:167-71.

5.
6.

A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor.

Kumar S, Villinger F, Oakley M, Aguiar JC, Jones TR, Hedstrom RC, Gowda K, Chute J, Stowers A, Kaslow DC, Thomas EK, Tine J, Klinman D, Hoffman SL, Weiss WW.

Immunol Lett. 2002 Apr 1;81(1):13-24.

PMID:
11841841
7.

Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.

Jeamwattanalert P, Mahakunkijcharoen Y, Kittigul L, Mahannop P, Pichyangkul S, Hirunpetcharat C.

Clin Vaccine Immunol. 2007 Apr;14(4):342-7. Epub 2007 Feb 21.

8.

Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.

Leal MT, Camacho AG, Teixeira LH, Bargieri DY, Soares IS, Tararam CA, Rodrigues MM.

Clin Vaccine Immunol. 2013 Sep;20(9):1418-25. doi: 10.1128/CVI.00312-13. Epub 2013 Jul 17.

9.

Adjuvant requirement for successful immunization with recombinant derivatives of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal route.

Bargieri DY, Rosa DS, Lasaro MA, Ferreira LC, Soares IS, Rodrigues MM.

Mem Inst Oswaldo Cruz. 2007 Jun;102(3):313-7.

13.

Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.

Xue X, Ding F, Zhang Q, Pan X, Qu L, Pan W.

Vaccine. 2010 Apr 19;28(18):3152-8. doi: 10.1016/j.vaccine.2010.02.054. Epub 2010 Mar 1.

PMID:
20197139
14.

Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.

Sachdeva S, Mohmmed A, Dasaradhi PV, Crabb BS, Katyal A, Malhotra P, Chauhan VS.

Vaccine. 2006 Mar 15;24(12):2007-16. Epub 2005 Dec 6.

PMID:
16377036
15.

Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii.

Kawabata Y, Udono H, Honma K, Ueda M, Mukae H, Kadota J, Kohno S, Yui K.

Infect Immun. 2002 Nov;70(11):6075-82.

16.
17.
18.

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.

Tamborrini M, Stoffel SA, Westerfeld N, Amacker M, Theisen M, Zurbriggen R, Pluschke G.

Malar J. 2011 Dec 13;10:359. doi: 10.1186/1475-2875-10-359.

19.

[Influence of deleting 9 amino acid residues at N-terminus on immunogenicity of a Plasmodium falciparum chimeric protein].

Zhang QF, Pan WQ, Qu L, Xue XY.

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Apr;35(4):345-9. Chinese.

PMID:
12673388
20.

Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.

Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC, Robinson R, Long CA, Miller LH.

Infect Immun. 2001 Mar;69(3):1536-46.

Supplemental Content

Support Center